Information Provided By:
Fly News Breaks for December 30, 2019
Dec 30, 2019 | 14:55 EDT
Ladenburg analyst Matthew Kaplan raised his price target on shares of Axsome Therapeutics to $165 from $139 as he believes the "impressive" top-line AXS-07 MOMENTUM Phase 3 migraine study results increase the likelihood for approval of the drug. The analyst, who notes that Axsome plans to file a new drug application for AXS-07 in the second half of 2020, reiterated his Buy rating on the stock.
News For AXSM From the Last 2 Days
There are no results for your query AXSM